[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES529749A0 - Procedimiento para preparar (2-oxo-1, 2, 3, 5-tetrahidroimidazo (2, 1-b) quinazolinil) oxialquilamidas - Google Patents

Procedimiento para preparar (2-oxo-1, 2, 3, 5-tetrahidroimidazo (2, 1-b) quinazolinil) oxialquilamidas

Info

Publication number
ES529749A0
ES529749A0 ES529749A ES529749A ES529749A0 ES 529749 A0 ES529749 A0 ES 529749A0 ES 529749 A ES529749 A ES 529749A ES 529749 A ES529749 A ES 529749A ES 529749 A0 ES529749 A0 ES 529749A0
Authority
ES
Spain
Prior art keywords
sub
alkyl
carbon atoms
lower alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES529749A
Other languages
English (en)
Other versions
ES8604226A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of ES8604226A1 publication Critical patent/ES8604226A1/es
Publication of ES529749A0 publication Critical patent/ES529749A0/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/44Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
ES529749A 1983-02-16 1984-02-15 Procedimiento para preparar (2-oxo-1, 2, 3, 5-tetrahidroimidazo (2, 1-b) quinazolinil) oxialquilamidas Expired ES8604226A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/467,125 US4490371A (en) 1983-02-16 1983-02-16 N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides

Publications (2)

Publication Number Publication Date
ES8604226A1 ES8604226A1 (es) 1986-02-01
ES529749A0 true ES529749A0 (es) 1986-02-01

Family

ID=23854465

Family Applications (3)

Application Number Title Priority Date Filing Date
ES529749A Expired ES8604226A1 (es) 1983-02-16 1984-02-15 Procedimiento para preparar (2-oxo-1, 2, 3, 5-tetrahidroimidazo (2, 1-b) quinazolinil) oxialquilamidas
ES544202A Expired ES8603878A1 (es) 1983-02-16 1985-06-14 Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas
ES544203A Expired ES8603879A1 (es) 1983-02-16 1985-06-14 Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES544202A Expired ES8603878A1 (es) 1983-02-16 1985-06-14 Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas
ES544203A Expired ES8603879A1 (es) 1983-02-16 1985-06-14 Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas

Country Status (20)

Country Link
US (1) US4490371A (es)
EP (1) EP0116948B1 (es)
JP (1) JPS59155383A (es)
KR (1) KR840007727A (es)
AT (1) ATE49210T1 (es)
AU (1) AU572118B2 (es)
CA (1) CA1253862A (es)
DE (1) DE3480925D1 (es)
DK (1) DK70784A (es)
ES (3) ES8604226A1 (es)
FI (1) FI78097C (es)
GR (1) GR79543B (es)
HU (1) HU189886B (es)
IL (1) IL70964A (es)
NO (1) NO164476C (es)
NZ (1) NZ207156A (es)
PL (3) PL142959B1 (es)
PT (1) PT78106B (es)
SU (2) SU1349700A3 (es)
ZA (1) ZA841122B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU193409B (en) * 1984-02-15 1987-10-28 Syntex Inc Process for producing 2-square bracket -n-cyclohexyl-4-bracket-oxo-1,2,3,5-tetrahydro-imidazo-square bracket-2,1-b-square bracket closed-quinazolin-7-yl-bracket closed-oxy-alkqne-carboxamidyl-square bracket closed-alkan-acides
US4593029A (en) * 1984-02-15 1986-06-03 Syntex (U.S.A.) Inc. Novel ω-(N-imidazolyl)alkyl ethers of 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
GB8514207D0 (en) * 1985-06-05 1985-07-10 Pfizer Ltd Cardiac stimulants
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US4670434A (en) * 1985-11-14 1987-06-02 Syntex (U.S.A.) Inc. (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolinyl)oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4761416A (en) * 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US4739056A (en) * 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
NZ234186A (en) * 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
EP0523513A1 (de) 1991-07-05 1993-01-20 Byk Gulden Lomberg Chemische Fabrik GmbH Verwendung substituierter Pyridazine zur Behandlung von Dermatosen
US5348960A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
US5208237A (en) * 1992-04-03 1993-05-04 Bristol-Meyers Squibb Company 7-oxypropylsulfonamido-imidazo[4,5-b]quinolin-2-ones
US5196428A (en) * 1992-04-03 1993-03-23 Bristol-Myers Squibb Company Imidazo[4,5-b]qinolinyl oxy alkyl ureas
US5158958A (en) * 1992-04-03 1992-10-27 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl sulfonyl piperidine derivatives
CA2382547A1 (en) * 1999-09-21 2001-03-29 Stephen R. Hanson Methods and compositions for treating platelet-related disosders
EP1565472A2 (en) * 2002-11-27 2005-08-24 Artesian Therapeutics, Inc. Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
CA2662491A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
FR2910001B1 (fr) * 2006-12-18 2009-03-20 Sod Conseils Rech Applic Derives d'imidazo, pyrimido et diazepine pyrimidine-dione et leur utilisation comme medicament
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
GB0808950D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808944D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808953D0 (en) * 2008-05-16 2008-06-25 Shire Llc substituted quinazolines
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8586587B2 (en) 2009-02-26 2013-11-19 Thar Pharmaceuticals, Inc. Crystalline molecular complex of tadalafil and methylparaben
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR102034748B1 (ko) 2011-03-01 2019-10-21 시너지 파마슈티컬즈 인코포레이티드 구아닐레이트 사이클라제 c 작용제의 제조 방법
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN114404588A (zh) 2013-08-09 2022-04-29 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US4313947A (en) * 1974-06-24 1982-02-02 Otsuka Pharmaceutical Co., Ltd. Platelet aggregation inhibiting 2-oxyindoles, their compositions and method of use
US4070470A (en) * 1974-06-24 1978-01-24 Otsuka Pharmaceutical Co., Ltd. Platelet aggregation inhibiting carbostyrils, their compositions and method of use
NZ187452A (en) * 1977-06-10 1980-05-27 Otsuka Pharma Co Ltd N- substituted-aminocarbonylpropoxy-carbostyrils and their preparation
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
FR2512674B1 (fr) * 1981-09-16 1986-01-10 Sandoz Sa Nouveaux derives tricycliques de la quinazolinone, leur preparation et medicaments contenant ces derives
HU193409B (en) * 1984-02-15 1987-10-28 Syntex Inc Process for producing 2-square bracket -n-cyclohexyl-4-bracket-oxo-1,2,3,5-tetrahydro-imidazo-square bracket-2,1-b-square bracket closed-quinazolin-7-yl-bracket closed-oxy-alkqne-carboxamidyl-square bracket closed-alkan-acides

Also Published As

Publication number Publication date
DK70784D0 (da) 1984-02-15
PL143010B1 (en) 1987-12-31
ATE49210T1 (de) 1990-01-15
DE3480925D1 (de) 1990-02-08
IL70964A0 (en) 1984-05-31
GR79543B (es) 1984-10-30
SU1349700A3 (ru) 1987-10-30
CA1253862A (en) 1989-05-09
US4490371A (en) 1984-12-25
ES8603878A1 (es) 1986-01-16
AU2460584A (en) 1984-08-23
IL70964A (en) 1987-08-31
JPS59155383A (ja) 1984-09-04
ZA841122B (en) 1985-09-25
FI78097C (fi) 1989-06-12
FI78097B (fi) 1989-02-28
ES8604226A1 (es) 1986-02-01
EP0116948A2 (en) 1984-08-29
NO164476B (no) 1990-07-02
PL142959B1 (en) 1987-12-31
EP0116948A3 (en) 1984-12-19
KR840007727A (ko) 1984-12-10
PL142960B1 (en) 1987-12-31
PL253009A1 (en) 1985-09-10
FI840603A (fi) 1984-08-17
AU572118B2 (en) 1988-05-05
DK70784A (da) 1984-08-17
PL246224A1 (en) 1985-08-27
SU1493109A3 (ru) 1989-07-07
PL253010A1 (en) 1985-09-10
FI840603A0 (fi) 1984-02-15
HU189886B (en) 1986-08-28
ES8603879A1 (es) 1986-01-16
ES544202A0 (es) 1986-01-16
ES544203A0 (es) 1986-01-16
NO840551L (no) 1984-08-17
PT78106A (en) 1984-03-01
NO164476C (no) 1990-10-10
EP0116948B1 (en) 1990-01-03
PT78106B (en) 1986-06-02
NZ207156A (en) 1987-07-31

Similar Documents

Publication Publication Date Title
ES544202A0 (es) Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas
GR3004250T3 (es)
ZM3785A1 (en) Bis-(4 aminopheny-l)-sulfones
ES8401014A1 (es) Un procedimiento para la preparacion de nuevos derivados de propanolamina.
ES2000456A6 (es) Procedimiento para preparar deirvados de acido eicosatriinoico-5,8,11 y utilizacion de estos en composiciones farmaceuticas y cosmeticas.
ES8105266A1 (es) Un procedimiento para la preparacion de aminoeteres.
ATE62663T1 (de) Indan-derivate, verfahren zu ihrer herstellung und die erhaltenen zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende zusammensetzungen.
ES8607235A1 (es) "4-(nitrofenil)-tetrahidropiridinas,procedimiento para su obtencion y su empleo como medicamento"
GB8823405D0 (en) Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
KR880012545A (ko) 피롤알데히드 이의 제조방법 및 용도
DK0971899T3 (da) Hexahydroindenopyridinforbindelser med antispermatogen virkning
DE69116680D1 (de) Imidazol-2-yl-derivate von bicyclischen verbindungen und verfahren zu deren herstellung
GB1167605A (en) Improvements in or relating to Nucleosides and the Manufacture Thereof
ES8500620A1 (es) Procedimiento para la preparacion de derivados e-homo-eburnanos racemicos u opticamente activos y de sus sales de adicion acidas.